20 May 2013
Keywords: Biogen Idec, Exec VPs, R&D, Corporate development
Article | 06 January 2011
After last November announcing a restructuring and refocusing of its therapeutic directions last year, US biotech firm Biogen Idec (Nasdaq: ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.